RNA NASDAQ
Atrium Therapeutics, Inc.
1W: -5.4%
1M: -44.2%
3M: -39.7%
YTD: -89.1%
1Y: -82.0%
3Y: +22.9%
5Y: -67.7%
$7.84
-0.30 (-3.69%)
Weekly Expected Move ±11.5%
$6
$7
$8
$9
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$134.1M
52W Range7.68-16.77
Volume533,802
Avg Volume243,432
Beta0.37
Dividend—
Analyst Ratings
Company Info
CEOKathleen Gallagher
Employees511
SectorHealthcare
IndustryBiotechnology
IPO Date2026-02-27
Websiteatriumtherapeutics.com
10578 Science Center Drive
San Diego, CA 92121
US
San Diego, CA 92121
US
619 876 0700
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Latest News
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences, Inc. $RNA Shares Sold by Assetmark Inc.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Younis Husam | F-InKind | 11,216 | $8.95 | 2026-09-18 |
| Hughes Steven George | F-InKind | 21,459 | $8.95 | 2026-09-18 |
| Flanagan W. Michael | F-InKind | 22,812 | $8.95 | 2026-09-18 |
| Boyce Sarah | F-InKind | 126,418 | $8.95 | 2026-09-18 |
| Kenney Stephanie | F-InKind | 2,375 | $8.95 | 2026-09-18 |